BTCC / BTCC Square / Global Cryptocurrency /
CRISPR Therapeutics CEO’s Stock Sales Trigger Market Reaction

CRISPR Therapeutics CEO’s Stock Sales Trigger Market Reaction

Published:
2026-01-24 14:32:21
12
3
BTCCSquare news:

CRISPR Therapeutics AG (CRSP) shares fell 5.8% this week following CEO Samarth Kulkarni's sale of $5.17 million in company stock. The transactions, executed at $51.75 and $60.23 per share respectively, reduced Kulkarni's direct holdings by 40%.

Bank of America maintained its bullish outlook despite trimming its price target to $89, citing tempered expectations for Casgevy's 2026 performance. The analyst consensus remains neutral with a $68.15 average target, reflecting the biotech sector's characteristic volatility.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.